US court rejects Jazz attempt to revive Xyrem patents

The US Court of Appeals for the Federal Circuit has rejected Jazz Pharmaceuticals’ attempt to revive patents covering its narcolepsy drug Xyrem (sodium oxybate).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Jazz Pharmaceuticals acquires UK medical cannabis firm for $7.2bn

4 February 2021 Jazz Pharmaceuticals has acquired UK medicinal cannabis company GW Pharmaceuticals in a takeover worth $7.2 billion.

Americas

Hikma enters settlement agreement with Jazz to sell Xyrem generic

7 April 2017 Hikma Pharmaceuticals has entered into a settlement agreement with Jazz Pharmaceuticals, following a patent infringement dispute related to Jazz’s drug Xyrem.

Americas

Jazz plays on as Xyrem challenges quashed

15 January 2015 The US Patent and Trademark Office has rejected several petitions that challenged a patent covering Jazz Pharmaceuticals’ narcolepsy drug Xyrem (sodium oxybate).

More on this story

Big Pharma

Jazz Pharmaceuticals acquires UK medical cannabis firm for $7.2bn

4 February 2021 Jazz Pharmaceuticals has acquired UK medicinal cannabis company GW Pharmaceuticals in a takeover worth $7.2 billion.

Americas

Hikma enters settlement agreement with Jazz to sell Xyrem generic

7 April 2017 Hikma Pharmaceuticals has entered into a settlement agreement with Jazz Pharmaceuticals, following a patent infringement dispute related to Jazz’s drug Xyrem.

Americas

Jazz plays on as Xyrem challenges quashed

15 January 2015 The US Patent and Trademark Office has rejected several petitions that challenged a patent covering Jazz Pharmaceuticals’ narcolepsy drug Xyrem (sodium oxybate).

More on this story

Big Pharma

Jazz Pharmaceuticals acquires UK medical cannabis firm for $7.2bn

4 February 2021 Jazz Pharmaceuticals has acquired UK medicinal cannabis company GW Pharmaceuticals in a takeover worth $7.2 billion.

Americas

Hikma enters settlement agreement with Jazz to sell Xyrem generic

7 April 2017 Hikma Pharmaceuticals has entered into a settlement agreement with Jazz Pharmaceuticals, following a patent infringement dispute related to Jazz’s drug Xyrem.

Americas

Jazz plays on as Xyrem challenges quashed

15 January 2015 The US Patent and Trademark Office has rejected several petitions that challenged a patent covering Jazz Pharmaceuticals’ narcolepsy drug Xyrem (sodium oxybate).

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB

US court rejects Jazz attempt to revive Xyrem patents

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features